Raxibacumab
Based on 1 publication(s) in Google Scholar
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.88%
- CAS. Nr.: 565451-13-0
- Molecular Weight:142.96 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Raxibacumab
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
anthrax protective antigen
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:In SD rats after the initiation of a 24-h LeTx infusion[3]
-
Dosage:150 μg/kg or 300 μg/kg
-
Administration:At the time of or 3, 6, 9, or 12 h after the initiation of LeTx infusion, the rats were randomized to be treated i.v. in a single dose
-
Result:Significantly improved in outcome when it was administered up to 6 h (and approached significance when administered up to 12 h) after initial exposure to LeTx.
Rats receiving raxibacumab within 6 hours of toxin administration had a better survival rate than those that received raxibacumab at 9 or 12 hours.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 565451-13-0
-
Appearance Liquid
-
Molecular Weight 142.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Raxibacumab]
-
Synonyms
ABthrax
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Mazumdar S. Raxibacumab. MAbs.2009 Nov-Dec;1(6):531-8. [Content Brief]
[2]. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist. 2014 Apr 29;7:101-9. [Content Brief]
[3]. Cui X, et.al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis. 2005 Feb 1;191(3):422-34. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Raxibacumab Related Classifications
HY-P9957 Related Classifications
Powered by Bioz